IDEXX Laboratories stock gains attention after CoVetAI deal and Stifel Buy rating
Published on 09/20/2026 at 10:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IDEXX Laboratories stock (ISIN US45168D1046) is trading near USD 506.48 on Nasdaq, leaving the shares well below a reiterated USD 675.00 price target from Stifel as of September 18, 2026. As Yahoo Finance reported on September 16, 2026, IDEXX Laboratories has also agreed to acquire veterinary software firm CoVetAI, adding an artificial intelligence documentation tool to its portfolio.
AI acquisition expands IDEXX software offering
According to Yahoo Finance on September 16, 2026, IDEXX Laboratories announced that it had bought CoVetAI, a fast-growing veterinary software company whose tool listens during appointments and organizes what is said and done in the clinic. The article notes that the acquisition aims to help veterinarians cut documentation time and potentially increase billable services by automatically capturing procedures and diagnostics in the medical record.
The same report highlights that IDEXX Laboratories trades on Nasdaq under the ticker IDXX and that investors value the group at a forward price-earnings multiple of about 30.86 based on estimates as of September 18, 2026. This valuation multiple, which reflects expectations for earnings growth rather than current reported results, positions the company toward the higher end of the healthcare diagnostics peer range and underlines that growth initiatives such as CoVetAI are strategically important.
Stifel reiterates Buy with USD 675 target
In addition to the AI deal, IDEXX Laboratories stock is supported by a recent analyst view from Stifel. As a corporate news summary on September 19, 2026 indicates, Stifel reaffirmed a Buy rating on IDEXX Laboratories stock and maintained a price target of USD 675.00 on September 18, 2026, when the shares closed near USD 506.48 on Nasdaq. With the stock roughly USD 168.52 below that target level, the implied upside indicated by the Stifel target is around one third of the current market price, although it depends on future execution.
Per the same summary based on data from Investing.com, IDEXX Laboratories stock traded in a 52-week range from USD 500.61 to USD 770.00 as of September 18, 2026, putting the latest price only about USD 5.87 above the 52-week low and USD 263.52 below the 52-week high. This wide range underscores how much the shares have pulled back from earlier peaks, while remaining close to technical support around the low.
Profitability metrics support long-term story
Beyond the latest analyst commentary, performance metrics show that IDEXX Laboratories is among the more profitable healthcare names. A ranking published on September 19, 2026 lists IDEXX Laboratories with a return on assets of 31.62 percent and a market capitalization of USD 39.90 billion, based on recent financial data. This figure, while not tied to a specific quarter in the snippet, signals that the company is converting its balance-sheet assets into earnings at a rate well above many diversified healthcare groups, which may help underpin its valuation over time.
Another portal summarizing IDEXX Laboratories as a water and veterinary diagnostics provider notes that the group develops, manufactures and distributes products primarily for companion animal veterinary markets, livestock and poultry producers, dairy operations and water testing customers across Africa, Asia Pacific, Canada, Europe, Latin America and other international regions. This broad customer base offers diversification across end markets, which can be helpful in absorbing regional demand swings but also exposes the company to currency and regulatory risks.
Stock trades near 52-week low on Nasdaq
Per recent Nasdaq price data referenced in a corporate news overview on September 19, 2026, IDEXX Laboratories stock closed at USD 506.48 on Nasdaq on September 18, 2026, with that closing price serving as the latest available reference for investors ahead of September 20, 2026. The same overview shows that this price sits close to the 52-week low of USD 500.61 and significantly below the 52-week high of USD 770.00, so the shares currently lie toward the bottom of their one-year trading band.
With a market capitalization around USD 39.90 billion as of mid-September 2026 and a relatively modest short interest of about 3.04 percent of the free float, IDEXX Laboratories stock combines large-cap liquidity with limited bearish positioning. For investors, the combination of a fresh AI-focused acquisition, high profitability and a price near the 52-week low forms the current backdrop for weighing upside potential against valuation and execution risks.
IDEXX Laboratories stock at a glance
- Company: IDEXX Laboratories, Inc.
- ISIN: US45168D1046
- Ticker: IDXX
- Trading venue: Nasdaq
- Price (as of September 18, 2026, 04:00): 506.48 USD
- Market capitalization: 39.90 billion USD (as of September 19, 2026)
- Sector / Industry: Healthcare - Veterinary diagnostics and water testing
- Index membership: S&P 500
